迈得医疗(688310) - 2024 Q4 - 年度业绩

Financial Performance - In 2024, the total operating revenue was 27,513.83 million yuan, a decrease of 42.71% compared to the previous year[3] - The net profit attributable to the parent company was -1,974.97 million yuan, representing a decline of 119.78% year-on-year[3] - The basic earnings per share were -0.12 yuan, down 119.67% from 0.61 yuan in the previous year[3] - The net profit attributable to the parent company after deducting non-recurring gains and losses was -2,630.79 million yuan, a decrease of 130.18% compared to the previous year[3] Assets and Equity - Total assets at the end of the reporting period were 105,364.26 million yuan, an 8.37% decrease from the previous year[6] - The equity attributable to the parent company was 81,028.15 million yuan, down 9.35% year-on-year[6] - The company recorded a 40.80% increase in share capital due to a capital reserve conversion plan implemented during the reporting period[9] Expenses and Investments - The company experienced increased R&D and management expenses due to ongoing investments in R&D projects and the development of new business lines[7] Market Conditions - The significant decline in operating performance was attributed to fluctuations in downstream market demand and increased competition in certain product markets[8] Financial Data Disclaimer - The company has indicated that the financial data presented is preliminary and subject to audit, urging investors to be aware of investment risks[10]